LG Life Sciences to conduct Phase 3 clinical trials over new diabetes treatment

Published: 2009-09-25 06:56:00

Updated: 2009-09-25 06:56:00

LG Life Sciences (LGLS), a Korean pharmaceutical manufacturer, said on September 22 that it will begin Phase III clinical trials for LC15-0444, a new anti-diabetic agent, in Korea and India.

LC15-0444, a dipeptidyl peptidase-4 (DPP-4) enzyme, is one of a new class of oral hypoglycemics that is...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK